Article Text

Download PDFPDF
Ovarian cancer—can intraperitoneal therapy be regarded as new standard in Germany?
  1. A. Du Bois*,
  2. B. Schmalfeldt,
  3. W. Meier,
  4. J. Sehouli§,
  5. J. Pfisterer,
  6. ARBEITSGEMEINSCHAFT GYNAEKOLOGISCHE ONKOLOGIE [AGO] KOMMISSION OVAR, THE AGO STUDY GROUP OVARIAN CANCER [AGO-OVAR], AND THE NORDDEUTSCHE GESELLSCHAFT FUER GYNAEKOLOGISCHE ONKOLOGIE [NOGGO]
  1. *Department of Gynecology and Gynecologic Oncology, Dr Horst Schmidt Klinik (HSK) Wiesbaden, Germany
  2. Department of Gynecology and Obstetrics, Klinikum rechts der Isar, Technical University of Munic, Germany
  3. Department of Obstetrics and Gynecology, Evangelisches Krankenhaus, Düsseldorf, Germany
  4. §Klinik fuer Frauenheilkunde und Geburtshilfe, Charitè/Campus Virchow-Klinikum Universitaetsmedizin Berlin, Germany
  5. Klinik für Gynäkologie und Geburtshilfe Campus Kiel, Universitätsklinikum Schleswig-Holstein, Germany
  1. Address correspondence and reprint requests to: Prof Andreas du Bois, MD, PhD, Gynecology & Gynecologic Oncology, Dr Horst Schmidt Klinik (HSK), Ludwig Erhard Street 100, D-65199 Wiesbaden, Germany. Email: dubois.hsk-wiesbaden{at}uumail.de

Abstract

The German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) and the two German cooperative study groups (AGO-OVAR and NOGGO) performed a review of the currently available literature on intraperitoneal first-line treatment in advanced ovarian cancer to consider if this new option should be incorporated into the German guidelines for treatment of ovarian cancer.

  • intraperitoneal therapy
  • guidelines
  • ovarian cancer
  • paclitaxel
  • platinum

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.